TPS742 Background: The first-line treatment for metastatic clear cell renal cell carcinoma
(mccRCC) includes an immuno-oncology (IO) based combination. The current standard
regimens include a PD-1 inhibitor plus either (1) an anti-CTLA-4 inhibitor (IO/IO), or (2) an
anti-vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor
(TKI)(IO/TKI). Currently, there is no level 1 evidence to guide physician's choice between an
IO/IO versus IO/TKI combination. The phase III IMmotion 151 trial performed RNA-seq from …

Background The first-line treatment for metastatic clear cell renal cell carcinoma (mccRCC)
includes immune oncology (IO) based combination therapy. The current standard includes a
PD-1 inhibitor plus either an anti-CTLA-4 inhibitor (IO/IO) or an anti-vascular endothelial
growth factor receptor tyrosine kinase inhibitor (VEGF TKI)(IO/TKI). Currently, there is no
evidence to guide a physician's choice between an IO/IO versus an IO/TKI combination. The
phase III IMmotion 151 trial performed RNA-seq from 823 ccRCC tumors and established …